Skip to main content
Teva Pharmaceutical Industries Ltd. logo

Teva Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · TEVA ISIN · US8816242098 LEI · 549300BAFGM4RC74ZJ94 TA Manufacturing
Open in API
Filings indexed 6,049 across all filing types
Latest filing 2026-03-09 Director's Dealing
Country IL Israel
Listing TA TEVA

About Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical company that develops, produces, and markets a broad portfolio of medicines. The company's business is centered on two main segments: generic medicines and innovative specialty treatments. As one of the world's largest manufacturers of generic drugs, Teva provides a wide range of affordable products across numerous therapeutic areas. Its specialty and biopharmaceutical research focuses on developing novel treatments, with a significant emphasis on central nervous system (CNS) disorders, including therapies for schizophrenia, tardive dyskinesia, and bipolar disorder. The company's portfolio also includes complex generics, biosimilars, and active pharmaceutical ingredients (APIs), while leveraging advanced technologies to enhance drug development and manufacturing.

Recent filings

Filing Released Lang Actions
Immediate Report
Director's Dealing Classification · 1% confidence The document is a U.S. Securities and Exchange Commission (SEC) Form 4, which is the standard regulatory filing used to report changes in beneficial ownership of securities by company insiders (directors and officers). This specific document details transactions (acquisitions and sales) by an executive (Richard Daniell) of Teva Pharmaceutical Industries. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2026-03-09 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is a short regulatory filing (under 2,000 characters) from Teva Pharmaceutical Industries. It explicitly states 'Attached hereto is a report on: דיווח מיידי – שינוי בהחזקות נושא משרה' (Immediate Report - Change in Officer Holdings) and provides a filename for the actual report (Form_4). According to the 'Menu vs Meal' rule, since this is a short announcement providing a link/attachment to the actual report, it is classified as a Report Publication Announcement (RPA).
2026-03-09 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is a U.S. Securities and Exchange Commission (SEC) Form 4, which is the standard regulatory filing used to report changes in beneficial ownership of securities by company insiders (directors and officers). The text explicitly identifies the reporting person (Jover Placid), the issuer (Teva Pharmaceutical Industries Limited), and details specific transactions involving the acquisition and sale of shares. This falls under the category of 'Director's Dealing' as it documents personal share transactions by a company executive.
2026-03-09 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (1811 characters) from Teva Pharmaceutical Industries titled 'Immediate Report – Change in Officer Holdings'. It explicitly states that a report regarding the change in officer holdings is attached as a PDF ('Form_4_-_Placid_Jover_-_9_3_2026_isa.pdf'). According to the 'Menu vs Meal' rule, since this is a short announcement providing a link/attachment to the actual disclosure, it is classified as a Report Publication Announcement (RPA).
2026-03-09 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is a U.S. Securities and Exchange Commission Form 4, which is the standard regulatory filing used to report changes in beneficial ownership of securities by company insiders (directors and officers). This specific document details transactions (acquisitions and sales) made by Matthew Shields, an EVP at Teva Pharmaceutical Industries. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2026-03-09 English
Immediate Report
Director's Dealing Classification · 1% confidence The document is an 'Immediate Report' from Teva Pharmaceutical Industries regarding a 'change in holdings of an officer' (דיווח מיידי – שינוי בהחזקות נושא משרה). It explicitly states that a PDF form (Form 4) is attached. According to the 'Menu vs Meal' rule, since this is a short announcement notifying the public of an attached filing regarding director/officer share transactions, it is classified as a Report Publication Announcement (RPA).
2026-03-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.